examine the effectiveness of sequential vs. initial combination therapy. Selected patients had HbA1CՆ7 at initiation of combination therapy (baseline) and no prior insulin or DPP4i use. Initial combination was defined as initiation of PIO and DPP4i within 30 days of each other; sequential combination was defined as having PIO monotherapy for Ն 2 months and initiation of a DPP4i within 1 year of the initiation of PIO. Baseline characteristics were compared between cohorts using Wilcoxon rank-sum and chi-square tests. HbA1C reduction at months 4, 8, 12, and 16 from baseline was compared using linear models adjusting for demographic variables, baseline HbA1C, diabetes duration, comorbidities, and medications. RESULTS: Patients starting initial (nϭ250) and sequential (nϭ211) combination with PIO and DPP4i during 3/1/2010 -2/28/2011 were identified. Patients in the two cohorts were similar in demographics, disease duration, and most comorbidities; however, patients receiving initial combination therapy had higher average baseline HbA1C (8.6 vs. 8.0; PϽ0.001), a higher proportion with coronary artery disease (11.6% vs. 6.2%; Pϭ0.043), and lower proportions with hyperlipidemia (56.4% vs. 67.8%; P ϭ0.012) and hypertension (62.4% vs. 72.0%; P ϭ0.029). In adjusted analyses, initial combination therapy was associated with greater reduction in HbA1C at months 12 (0.98 vs. 0.82, Pϭ0.034) and 16 (1.45 vs. 1.24, Pϭ0.048) than sequential combination therapy. CONCLUSIONS: Initial combination therapy with PIO and DPP4i demonstrated a significantly greater reduction in HbA1C than sequential combination among patients with poorly controlled blood glucose.
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OBJECTIVES:
Injectable pen therapy with insulin glargine (GLA-P) or the glucagonlike peptide 1 (GLP-1) analog liraglutide (LIRA) may be initiated by type 2 diabetes mellitus (T2DM) patients failing oral antidiabetic therapy. Real-world treatment patterns among T2DM patients initiating these drugs were assessed using electronic medical record (EMR) data in this retrospective study. METHODS: The study included adult T2DM patients who initiated GLA-P or LIRA at seven US endocrinology practices. EMR data for Ն4 months before treatment initiation (baseline), baseline A1C and weight data, and Ն1 additional A1C measurement were available; patients had Ն2 visits during a minimum of six months follow-up. Baseline characteristics and clinical outcomes were assessed descriptively at the end of 1-year follow-up. Patients were stratified by whether they were injectable-naive (IN) or injectable-experienced (IE) at initiation. RESULTS: The study included 440 patients. At baseline, GLA-P patients (nϭ117), compared with LIRA patients (nϭ323), were older, had higher baseline A1C, and lower weight; more were male, fewer IE (60.7% vs 65.3%). Insulin/GLP-1 were the only injectable in 49.3%/31.3% of LIRA IE vs 62.0%/ 26.8% of GLA-P IE patients at baseline. Through follow-up, 88% of GLA-P and 91.6% of LIRA patients remained on study treatment. A1C was significantly reduced in all four treatment groups (range: Ϫ0.42% for LIRA IE to Ϫ1.38% for GLA-P IN). Weight loss/maintenance occurred in 74.2% of LIRA vs 41.3% of GLA-P patients. Mean change in weight/BMI was -2.5kg/-0.86kg/m2 for LIRA vs 2.4kg/0.85 kg/m2 for GLA-P patients. No severe hypoglycemic events were reported. CONCLUSIONS: Our data identify a trend in the real-world prescribing of LIRA and GLA-P to T2DM patients with considerably different clinical profiles. This introduces challenges when conducting real-world comparative effectiveness studies. Due to the small sample size and descriptive nature of this study, these data should be confirmed by future large scale studies. [HC] ) were used to identify adult US T2DM patients with A1C Ն7.0% previously on OADs only, who initiated GLA-P or LIRA in 2010 and had continuous health care coverage for Ն6 months before (baseline) and 9 months after (follow-up) initiation. Stringent 1:1 propensity score matching was used to balance observed baseline differences between the cohorts. RESULTS: Data were included for 350 matched patients from OI (175 per cohort) and 290 from HC (145 per cohort). Baseline characteristics were similar for the matched cohorts. During follow-up, treatment persistence was higher for GLA-P vs LIRA (OI: 63.4% vs 56.0%, Pϭ 0.213; HC: 68.3% vs 47.6%, PϽ0.001). There were no significant differences in A1C reduction from baseline among patients with available data. Hypoglycemia-related events occurred at similarly low rates in both cohorts. Mean diabetes-related drug costs were significantly lower among GLA-P vs LIRA patients (OI: $2,327 vs $3,121, PϽ0.001; HC: $2,149 vs $3,016, PϽ0.001). CONCLUSIONS: Pilot phase data from the INITIATOR study suggest that, for T2DM patients failing OADs, GLA-P may be associated with higher persistence, similar A1C reduction and low hypoglycemia rates, and lower diabetes drug costs compared to LIRA. These results should be considered exploratory, owing to small sample sizes and lack of weight data, and await confirmation by data from the full-phase INITIATOR study.
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REAL-WORLD COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS INITIATING INJECTABLE TREATMENTS FOR TYPE 2 DIABETES MELLITUS (T2DM): PILOT DATA FROM THE INITIATOR STUDY
PDB7 CLINICAL AND RESOURCE UTILIZATION OUTCOMES: ELDERLY TYPE 2 DIABETES PATIENTS INITIATING INSULIN PENS VERSUS VIALS
Eby E 1 , Frois C 2 , Guerin A 3 , Boggs JA 1 , Nyhuis A 1 , Swindle R 1 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Analysis Group, Inc., Boston, MA, USA, 3 Analysis Group, Ltee., Montreal, QC, Canada OBJECTIVES: To assess clinical and resource utilization outcomes between elderly type 2 diabetes patients initiating basal insulin analog administered via pens vs. vials. METHODS: An online survey of 352 U.S. primary care physicians was used to collect retrospective patient chart data on 500 elderly type 2 diabetes patients who initiated on basal insulin analog in 2009. Information on glycemic control, severe hypoglycemic events, and diabetes-related health care resource utilization was collected prior to initiation and over a 12-month study period following insulin initiation. Information on adherence, both objective (measured via proportion of days covered [PDC]) and physician-revised (based on a revision of the objective PDC) was also collected for the study period. Multivariate regression analyses were used to control for confounding factors. RESULTS: Over the study period, initiation on pens, compared to vials, was associated with HbA1c levels 0.14 points lower (Pϭ0.027). No differences were seen in the likelihood of reaching an HbA1c thresholds of 7% (hazard ratio [HR]ϭ1.05, Pϭ0.738), though the likelihood was 27% and 55% higher for pen initiators for HbA1c thresholds of 7.5% (HRϭ1.27, Pϭ0.041) and 8% (HRϭ1.55, PϽ0.001), respectively. Rates of severe hypoglycemic events, inpatient, outpatient, and endocrinologist visits were similar between cohorts, but rates of emergency room visits were 68% lower for the pen cohort (IRRϭ0.32, Pϭ0.017). No significant differences in objective adherence rates (PDC) were observed (Pϭ0.080), while physician-revised adherence levels indicated a 2.2 percentage point higher adherence level for the pen cohort (Pϭ0.034). CONCLUSIONS: Results from this study suggest that initiation on insulin pens, as compared to vials, may be associated with better glycemic control, fewer emergency room visits, and higher adherence levels (based on physician assessments) without an impact to the incidence of severe hypoglycemic events. Objective adherence and other resource utilization categories were not significantly different between the two cohorts.
PDB8 WEIGHT LOSS OF >3% OF BODY WEIGHT AFTER INITIATING NEW ANTI-DIABETIC THERAPY IS ASSOCIATED WITH GLYCEMIC CONTROL AT 6 MONTHS IN PATIENTS WITH TYPE 2 DIABETES
Mcadam-marx C 1 , Bellows BK 1 , Wygant GD 2 , Mukherjee J 3 , Unni S 1 , Ye X 1 , Iloeje UH 3 , Brixner D 1 1 University of Utah, Salt Lake City, UT, USA, Princeton, NJ, USA, Wallingford, CT, USA OBJECTIVES: We previously identified a correlation between weight loss and glycemic control in patients with type 2 diabetes (T2DM) newly treated with oral or GLP-1 inhibitor therapy in the real-world setting. This study expands on those findings by including previously treated patients and patients initiating insulin. METHODS: This cohort study included T2DM patients age Ն18 years in an electronic medical record database from 2008-2011 prescribed a class of anti-diabetic not previously used (index date), and with a baseline HbA1c Ն7.0%. Weight and HbA1c changes from baseline were assessed at 6-months. Patients who lost Ն3% of body weight and attained HbA1c goal (Ͻ7.0%) were identified. Logistic regression was used to describe the association between weight loss and glycemic control controlling for confounding factors, including initiation of insulin vs. other therapies. RESULTS: The study included 861 patients. Mean (SD) age was 58.7 (12.3) years; 54.8% were male. Most patients (85.9%) were prescribed a non-insulin agent. Baseline HbA1c was 8.7% (1.6); weight was 103.6 kg (23.6). At 6 months, mean weight change was -1.6 (5.3) kg (pϭ0.13) and 31.8% lost weight. Mean change in HbA1c was -1.2% (1.8) (pϽ0.001). Overall, 42.9% attained HbA1c goal while 64.2% of patients who lost weight and 32.9% of those who did not lose weight (pϽ0.001) attained goal. The OR for attaining HbA1c goal with weight loss Ն3% vs. no weight loss was 3.60 (95% CI 2.66, 4.87) and was not significantly affected by insulin use. CONCLUSIONS: Patients with uncontrolled T2DM prescribed a new class of antidiabetic and who lost weight were more likely to attain HbA1c goal at 6-months than those who did not lose weight. These data are consistent with T2DM treatment guidelines that emphasize the importance of weight loss and prioritization of anti-diabetes agents that are not associated with weight gain.
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OUTCOME OF FIXED DOSE RADIOACTIVE IODINE FOR THE TREATMENT OF HYPERTHYROIDISM
Obidiya SO 1 , Ogunjobi K 2 , Eniojukan JF 1 1 Niger Delta University, YENAGOA, Bayelsa State, Nigeria, 2 University College Hospital, Ibadan, Oyo, Nigeria OBJECTIVES: To determine: 1) the response or cure rate of hyperthyroidism to fixed doses of 370MBq (10mCi) and 555MBq (15mCi) Radioactive Iodine (RAI) therapy, and 2) the incidence of hypothyroidism at 6months post RAI therapy. METHODS: A retrospective review of the records of 20 hyperthyroid patients treated with radioiodine to determine response rate of hyperthyroidism to two fixed dose regimens of RAI therapy was carried out. Twelve (12) and 8 patients received 370MBq (10mCi) A494 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
